Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24388975 | 0.84 | GPR119 (0.41) | CYP11B2NAMPTACACBGPR119SCD5 | |
| SCHEMBL24389031 | 0.83 | TRPV3 (0.42) | CYP11B2NAMPTACACBGPR119 | |
| SCHEMBL29637622 | 0.81 | ABHD6 (0.36) | MEN1KMT2AACACBABHD6 | |
| SCHEMBL13004992 | 0.80 | POLB (0.50) | CYP11B2POLBNAMPTGPR119SCD5 | |
| SCHEMBL21940362 | 0.80 | MEN1 (0.49) | POLBMEN1KMT2AESR2GPR119 | |
| SCHEMBL29609790 | 0.79 | MAPK1 (0.51) | CYP11B2MEN1KMT2ANAMPTGPR119 | |
| SCHEMBL23902054 | 0.79 | MAPK1 (0.51) | CYP11B2MEN1KMT2ANAMPTGPR119 | |
| SCHEMBL22521307 | 0.77 | GPR119 (0.47) | CYP11B2POLBNAMPTACACBGPR119 | |
| SCHEMBL20511944 | 0.77 | POLB (0.40) | CYP11B2POLBMEN1KMT2AGPR119 | |
| SCHEMBL24335985 | 0.76 | GPR119 (0.46) | ESR2ACACBGPR119SCD5GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | HRH3, HRH4, HRH2 | CYP11B2 1079/4885POLB 4334/4885MEN1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.